Dr María Jose Serrano
Oncological Resarch department
Deputy director of liquid biopsy and Cancer Interception Group

Email : mjose.serrano@genyo.es
Phone: +34 958715500
Localization GENyO centre

Full contact details

M. Jose Serrano Fernández, PhD
Scientific Director of Liquid Biopsies Division
Liquid Biopsies & Cancer Interception group
Senior Reseach UGC Oncologia. Hospital Virgen de las Nieves
Email: mjose.serrano@genyo.es  | Web: www.genyo.es
Pfizer – Universidad de Granada – Junta de Andalucía Centre for Genomics and Oncological Research (GENYO). Granada | Spain |
Telf. +34 958 715 500  Fax  +34 958 637 071


PhD Bachelor health of sciences University of Jaén 2003
Post-Doc Dr Jose Juan Gaforio. University of Jaen 2005. Spain
Post-Doc Fernando Vidal-Vanaclocha. CIC-BIOGUNE -DOMINION PHARMAKINE 2008. Bilbao Spain
Post-Doc Dr Jose Juan Gaforio. University of Jaen 2010. Spain
Post-Doc Dr Jose A Lorente. University of Granada 2015. Spain
HEAD OF GROUP- University hospital Virgen de las Nieves de Granada- GENyO. 2015


The trajectory Dr. María José Serrano is based on oncological research and mainly focused on the area of liquid biopsy.

During her career she has made different stays in Spain (Bilbao, Pamplona, Barcelona) and abroad (Tromso Norway). Currently, she is scientific director of the Liquid Biopsy Group and Cancer Interception group (BL & M) at GENyO center and in the Oncology department in the University Hospital Virgen de las Nieves, in Granada. She is author of more than 35 articles, about the exciting field of Liquid Biopsy.

Currently, she leads national as international projects. These projects are focused on the study of circulating tumor cells, platelets and cell free tumor DNA in different solid tumors. In addition, currently leads a national project funded by European commission to clinical implementation of LB in the Andalusian Hospitals (Innovative public purchase). Results of these projects have generated internationally licensed patents, the last of these patents is focused in a new methodology to detect circulating pulmonary cells in COPD patients.

Work carried out by her group has been recognized by the Health Ministry and the Andalusian Health Service (SAS).

Funding Sources

  • Instituto de Salud Carlos III
  • European scientific program H2020
  • Andalusian Government. Consejería de Salud
  • Science and Innovation spanish government
  • Spanish society of Pneumology
  • Roche Pharma
  • Spanish Society of Surgeon
  • Andalusian Government AGENCIA IDEA
  • Janssen Pharma
  • University of Granada
  • Caixa Foundation

Teaching interests

  • Health Sciences
  • Pathological anatomy


1 Scientific paper. Diego de Miguel-Perez; et al; MJ Serrano. 2019. Extracellular vesicle-miRNAs as liquid biopsy biomarkers for disease identification and prognosis in metastatic colorectal cancer patients Scientific Reports. Nature. ISSN 2045-2322.

2 Scientific paper. Diego de Miguel -Perez; et al; MJ Serrano. 2019. Post-surgery circulating tumor cells and AXL overexpression as new poor prognostic biomarkers in resected lung adenocarcinoma Cancers. MDPI. 11-11, pp.1750. ISSN 2072-6694.

3 Scientific paper. Serrano MJ. 2019. Cooperative and Escaping Mechanisms between Circulating Tumor Cells and Blood Constituents.Cells. MID. 8-11, pp.1382-1385. ISSN 2073-4409.

4 Scientific paper. Ortega FG; Serrano MJ; Fernandez baldo MA. 2019. EGFR detection in extracellular vesicles of breast cancer patients through immunosensor based on silica-chitosan nanoplatform Talanta. Elservier. 194, pp.243-252. ISSN 0039-9140.

5 Scientific paper. Rodríguez-Martínez A; de Miguel-Pérez D; Serrano MJ. 2019. Exosomal miRNA profile as complementary tool in the diagnostic and prediction of treatment response in localized breast cancer under neoadjuvant chemotherapy.Breast cancer research. Springer Nature. 21-1, pp.21-26. ISSN 1465-542X.

6 Scientific paper. Malapelle U; et al. 2019. Detection of epidermal growth factor receptor mutations in circulating tumor DNA: reviewing BENEFIT clinical trial.Journal Thoracic Disease. pISSN: 2072-1439; eISSN: 2077-6624. 10-12, pp.6388-6391. ISSN 2077-6624.

7 Scientific paper. Pedro J Romero; Serrano MJ. 2019. Liquid biopsy beyond cancer: Circulating Pulmonary Cells as biomarkers of COPD aggressivity Critical Review in Oncology and Hematology. 136, pp.31-36. ISSN 1040-8428.
8 Scientific paper. Delgado-Ureña M; Serrano. 2018. Circulating tumor cells criteria (CyCAR) versus standard RECIST criteria for treatment response assessment in metastatic colorectal cancer patients.J Transl Med.16-1, pp.251-256. ISSN 1479-5876.

9 Scientific paper. Puche-Sanz I; et al. 2017. A comprehensive study of circulating tumour cells at the moment of prostate cancer diagnosis: Biological and clinical implications of EGFR, AR and SNPs.Oncotarget. 1949-2553. ISSN 1949-2553.

10 Scientific paper. Bayarri-Lara CI; et al. 2017. Association of circulating tumour cells with early relapse and 18F-fluorodeoxyglucose positron emission tomography uptake in resected non-small-cell lung cancers†.Eur J Cardiothorac Surg. oxford academy. ISSN 1010-7940.

11 Scientific paper. C Bayarri; et al. 2016. Circulating Tumor Cells Identify Early Recurrence in Patients with Non-Small Cell Lung Cancer Undergoing Radical Resection Plos One. 11-2. ISSN 1932-6203.

12 Scientific paper. J Torres; et al. 2016. Prognostic factor analysis of circulating tumor cells in peripheral blood of patients with peritoneal carcinomatosis of colon cancer origin treated with cytoreductive surgery plus an intraoperative hyperthermic intraperitoneal chemotherapy procedure (CRS + HIPEC).Surgery. 159-3, pp.728-35. ISSN 0039-6060.

13 Scientific paper. FG Ortega; et al. 2015. Study of antitumor activity in breast cell lines using silver nanoparticles produced by yeast.Int J Nanomedicine. 16-10, pp.2021-2031.

14 Scientific paper. Ortega FG; et al. 2015. miRNA in situ hybridization in circulating tumor cells–MishCTC Sci Rep.17-5, pp.9207. ISSN 2045-2322.

15 Scientific paper. MJ Serrano; et al. 2014. EMT and EGFR in CTCs cytokeratin negative non-metastatic breast cancer.Oncotarget. 15-5, pp.7486-7497. ISSN 1949-2553.

16 Scientific paper. R Nadal; et al. 2013. CD133 expression in circulating tumor cells from breast cancer patients: potential role in resistance to chemotherapy.Int J Cancer. 133-10, pp.2398-2407. ISSN 1097-0215.

17 Scientific paper. A Fernández; et al. 2012. Biomarkers characterization of circulating tumour cells in breast cancer patients.Breast Cancer Re. 14-3, pp.R71. ISSN 1465-542X.

18 Scientific paper. R Rosell; MA Molina; MJ Serrano. 2012. EGFR mutations in circulating tumour DNA.Lancet Oncol.3-10, pp.971-973. ISSN 1470-2045.

19 Scientific paper. MJ Serrano; et al. 2011. Circulating cancer cells in division in an early breast cancer patient.Ann Oncol.22-9, pp.21-25. ISSN 0923-7534.

20 Review. Rolfo C; et al; Serrano MJ. 2020. Challenges and opportunities of cfDNA analysis implementation in clinical practice: Perspective of the International Society of Liquid Biopsy (ISLB) Journal of Clinical Oncology. ASCO. APRIL. ISSN 1527-7755.